Nociceptin Receptor (NOP) neurons express the nociceptin/orphanin FQ (N/OFQ) peptide receptor, also known as the opioid receptor-like 1 (OPRL1). These neurons constitute a distinct neuromodulatory system involved in pain transmission, reward processing, anxiety, learning, and neuroendocrine control.
| Property |
Value |
| Receptor Name |
Nociceptin Receptor (NOP/OPRL1) |
| Endogenous Ligand |
Nociceptin/Orphanin FQ (N/OFQ) |
| Gene Symbol |
OPRL1 |
| G Protein |
Gi/o (inhibitory) |
| Primary Location |
Cortex, Hippocampus, Amygdala, Spinal Cord |
The NOP receptor is a Class A G protein-coupled receptor (GPCR) with:
- Seven transmembrane domains
- N-terminal extracellular domain involved in ligand binding
- C-terminal intracellular domain for G protein coupling
- Multiple splice variants with distinct pharmacological profiles
NOP receptor activation triggers multiple intracellular pathways:
| Pathway |
Effect |
| Gi/o protein |
Inhibits adenylate cyclase, reduces cAMP |
| MAPK cascades |
ERK1/2, p38, JNK activation |
| Ion channels |
Activates GIRKs, inhibits VGCCs |
| Beta-arrestin |
Mediates receptor internalization |
¶ Ligand: Nociceptin/Orphanin FQ
Nociceptin is a 17-amino acid neuropeptide structurally related to dynorphin A but with distinct pharmacological properties:
- Precursor: Prepronociceptin (PNOC) gene
- Post-translational processing: Produces N/OFQ and related peptides
- Distribution: Widespread in CNS and peripheral nervous system
- Physiological roles: Pain modulation, reward, anxiety, learning, memory
Cerebral Cortex:
- Layer II/III pyramidal neurons: High NOP expression
- Layer V corticotegmental neurons: Moderate expression
- Parvalbumin+ interneurons: NOP present in some subpopulations
- Functions: Cortical plasticity, sensory processing
Hippocampus:
- CA1 pyramidal cells: NOP modulates synaptic plasticity
- CA3 pyramidal cells: Involved in memory consolidation
- Dentate gyrus granule cells: Regulation of neurogenesis
- Hippocampal interneurons: NOP inhibits GABA release
- Role in neurodegeneration: NOP dysregulation contributes to memory deficits in AD
Amygdala:
- Central nucleus: High NOP density, anxiety regulation
- Basolateral amygdala: Emotional memory processing
- Bed nucleus of the stria terminalis: Stress responses
- Role in neurodegeneration: NOP alterations in AD and PD
Basal Ganglia:
- Striatum: Modulates dopaminergic signaling
- Substantia nigra pars compacta: NOP affects dopamine neuron survival
- Globus pallidus: Motor control functions
- Role in PD: NOP agonists may protect dopamine neurons
Raphe Nuclei:
- Dorsal raphe: Mood regulation
- Median raphe: Anxiety-related behaviors
- NOP modulates serotonergic transmission
Locus Coeruleus:
- Noradrenergic neurons express NOP
- Nociceptin reduces norepinephrine release
- Role in AD: LC noradrenergic degeneration is early event
Periaqueductal Gray (PAG):
- NOP in pain modulation circuits
- Involved in descending pain inhibition
- Dorsal horn: NOP on primary afferents and interneurons
- Lamina I-II: Nociceptin reduces pain transmission
- Motor neurons: NOP effects on spinal motor circuits
- Clinical relevance: NOP agonists as analgesic agents
¶ Functions and Physiology
NOP neurons exhibit bidirectional pain modulatory effects:
Peripheral Analgesia:
- NOP agonists produce analgesia at peripheral sites
- Effective in inflammatory and neuropathic pain models
- Limited abuse potential compared to traditional opioids
Spinal Analgesia:
- NOP activation inhibits substance P release
- Reduces dorsal horn neuron excitability
- Synergistic effects with mu-opioid receptor agonists
Supraspinal Effects:
- Complex effects on pain perception
- Nociceptin can produce both analgesic and pro-nociceptive effects
- Context-dependent actions based on brain region
¶ Reward and Motivation
The NOP system interacts with mesolimbic dopamine pathways:
- VTA dopamine neurons: NOP modulates firing rate
- Nucleus accumbens: N/OFQ reduces reward-seeking behavior
- Prefrontal cortex: Affects decision-making and impulsivity
- Clinical relevance: NOP antagonists as potential antidepressants
¶ Anxiety and Emotional Processing
- Anxiogenic effects: Nociceptin administration increases anxiety
- Amygdala function: NOP regulates fear and anxiety responses
- Stress response: N/OFQ released during stress
- Potential therapy: NOP antagonists for anxiety disorders
¶ Learning and Memory
- Hippocampal plasticity: NOP modulates LTP and LTD
- Memory consolidation: N/OFQ affects recall
- Spatial learning: NOP in place cell function
- Neurodegeneration: NOP alterations in AD models
- Hypothalamic regulation: NOP affects pituitary hormone release
- CRH/ACTH: N/OFQ modulates stress axis
- Growth hormone: NOP influences GH secretion
- Prolactin: N/OFQ effects on prolactin release
NOP System Alterations:
- NOP receptor binding reduced in AD hippocampus
- N/OFQ levels elevated in CSF of AD patients
- Correlation with cognitive decline severity
Potential Mechanisms:
- NOP dysregulation contributes to memory impairment
- Interactions with amyloid-beta pathology
- Effects on tau phosphorylation
Therapeutic Approaches:
- NOP agonists: Memory enhancement potential
- NOP antagonists: May reduce amyloid toxicity
- Clinical trials ongoing
NOP Involvement:
- NOP receptors on dopaminergic neurons
- N/OFQ neuroprotective effects in PD models
- NOP agonists reduce levodopa-induced dyskinesias
Therapeutic Potential:
- NOP modulation as adjunct to dopaminergic therapy
- Neuroprotection in early PD
- Motor complication management
- NOP system alterations in ALS models
- Motor neuron vulnerability and NOP
- Potential therapeutic targeting
- Huntington's Disease: NOP in basal ganglia dysfunction
- Frontotemporal Dementia: NOP in emotional processing
- Multiple System Atrophy: Autonomic function modulation
Clinical Candidates:
- SCH-221510: NOP agonist, analgesic development
- Ro64-6198: NOP agonist, anxiety/pain
- MCOPPB: Potent NOP agonist
Applications:
- Chronic pain management
- Parkinson's disease (neuroprotection)
- Addiction treatment (reduce reward)
- Pruritus (itch)
Clinical Candidates:
- SB-612111: NOP antagonist
- J-113397: Selective NOP antagonist
- LY2940094: NOP antagonist, depression
Applications:
- Depression and anxiety
- Alcohol use disorder
- Cognitive enhancement in AD
- Weight management
- Mollereau C, et al. Structure, pharmacology and roles of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2005
- Witkin JM, et al. The nociceptin/orphanin FQ receptor: target for novel CNS therapeutics. Pharmacol Ther. 2014
- Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1983
- NOP receptor in pain modulation (2019)
- Nociceptin and Alzheimer's disease (2020)
- NOP in Parkinson's disease models (2021)
- Nociceptin and anxiety (2018)
- NOP receptor agonists in clinical development (2022)